Valenti WM, Phoenix J, Patel R, et al. Integrating Long-acting Injectable Cabotegravir for PrEP into Standard of Care for Cisgender Women, Transgender Women, Transgender Men, and Men Who Have Sex with Men: Results from the PILLAR & EBONI Studies, Poster 1547 presented at IDWeek 2023, October 11-15, 2023, Boston, MA. Access at https://doi.org/10.1093/ofid/ofad500.1382
Dandachi D, Cunningham D, Valenti WM, et al. Perspectives of People with HIV (PWH) 6 Months Following a Switch to Cabotegravir and Rilpivirine Long-acting (CAB+RPV LA) in an Observational Real-world US Study (BEYOND), Poster 1567, IDWeek 2023, October 11-15, 2023, Boston, MA. Access at https://doi.org/10.1093/ofid/ofad500.1402
Zuppelli AR, Scutaru J, Danforth A, et al. Interim Analysis of Real-World Community-Based HIV Rapid Start Antiretroviral with BFTAF Versus Conventional HIV Antiretroviral Therapy Start – The RoCHaCHa Study, A Pilot Study. Poster 880 presented at IDWeek 2021, September 29- October 3, 2021, Virtual conference. Access at https://doi.org/10.1093/ofid/ofab466.1075
Zuppelli AR, Mancenido M, Scutaru J, et al. Real World Community-Based HIV Rapid Start Antiretroviral with BFTAF Versus Conventional HIV Antiretroviral Therapy Start – The RoCHaCHa Study, a Pilot Study, Poster 1039 presented at IDWeek 2020, October 21-25, 2020, Virtual conference. Access at https://doi.org/10.1093/ofid/ofaa439.1225
Braksmaier A, McMahon J, Chen SR, et al. Willingness to Take PrEP for HIV Prevention: The Combined Effects of Race/Ethnicity and Provider Trust. AIDS Education and Prevention. 2018; 30: 1 12. https://guilfordjournals.com/doi/abs/10.1521/aeap.2018.30.1.1?af=R&